- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01428453
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's Disease
A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) on Biomarkers Related to the Pathogenesis and Progression of Alzheimer's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria, 1431
- GSK Investigational Site
-
Sofia, Bulgaria, 1113
- GSK Investigational Site
-
-
-
-
Ontario
-
Toronto, Ontario, Canada, M3B 2S7
- GSK Investigational Site
-
-
Quebec
-
Gatineau, Quebec, Canada, J9A 1K7
- GSK Investigational Site
-
Sherbrooke, Quebec, Canada, J1H 1Z1
- GSK Investigational Site
-
-
-
-
Baden-Wuerttemberg
-
Ellwangen, Baden-Wuerttemberg, Germany, 73479
- GSK Investigational Site
-
Tuebingen, Baden-Wuerttemberg, Germany, 72076
- GSK Investigational Site
-
Ulm, Baden-Wuerttemberg, Germany, 89081
- GSK Investigational Site
-
-
Bayern
-
Alzenau, Bayern, Germany, 63755
- GSK Investigational Site
-
-
Hessen
-
Bad Homburg, Hessen, Germany, 61348
- GSK Investigational Site
-
-
Niedersachsen
-
Achim, Niedersachsen, Germany, 28832
- GSK Investigational Site
-
Hannover, Niedersachsen, Germany, 30559
- GSK Investigational Site
-
-
Nordrhein-Westfalen
-
Bochum, Nordrhein-Westfalen, Germany, 44787
- GSK Investigational Site
-
Bochum, Nordrhein-Westfalen, Germany, 44791
- GSK Investigational Site
-
Bochum, Nordrhein-Westfalen, Germany, 44892
- GSK Investigational Site
-
Koeln, Nordrhein-Westfalen, Germany, 50935
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Oldenburg, Schleswig-Holstein, Germany, 26122
- GSK Investigational Site
-
-
-
-
Lazio
-
Roma, Lazio, Italy, 00185
- GSK Investigational Site
-
-
Liguria
-
Genova, Liguria, Italy, 16132
- GSK Investigational Site
-
-
Lombardia
-
Brescia, Lombardia, Italy, 25125
- GSK Investigational Site
-
Milano, Lombardia, Italy, 20122
- GSK Investigational Site
-
-
Veneto
-
Verona, Veneto, Italy, 37134
- GSK Investigational Site
-
-
-
-
-
Lørenskog, Norway, 1478
- GSK Investigational Site
-
-
-
-
-
Baracaldo/Vizcaya, Spain, 48903
- GSK Investigational Site
-
Barcelona, Spain, 08014
- GSK Investigational Site
-
Castellón de La Plana, Spain, 12004
- GSK Investigational Site
-
Getafe/Madrid, Spain, 28905
- GSK Investigational Site
-
L'Hospitalet de Llobregat, Spain, 08907
- GSK Investigational Site
-
Madrid, Spain, 28006
- GSK Investigational Site
-
-
-
-
-
Stockholm, Sweden, SE-141 86
- GSK Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A clinical diagnosis of possible Alzheimer's disease in accordance with the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with radiological (Magnetic Resonance Imaging [MRI] or Computed Tomography [CT]) evidence of significant cerebrovascular disease (CVD), assessed within the last 12 months
- Male or female between 50 and 80 years of age inclusive, at the time of signing the informed consent.
- Subject has a documented history of at least 6 months of ongoing Alzheimer's disease therapy (AChEIs and/or memantine) with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
- Mini-Mental Status Examination (MMSE) score between 20 and 26 at Screening.
- Clinical Dementia Rating Scale (CDR) score of 0.5 or 1.0 at Screening.
- A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea; or of child-bearing potential and agrees to use acceptable contraception methods
- Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if the subject is unable to provide informed consent due to cognitive status, the subject will provide assent and full written informed consent will be provided by a legally acceptable representative
- The subject has a dedicated caregiver who is willing to supervise participation in the study
- In the opinion of the investigator, the subject has the ability to comply with study procedures (cognitive and other testing) and is fluent in the language used for the administration of the cognitive tests.
Exclusion Criteria:
- History and/or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. structural or developmental abnormality, epilepsy, infectious, degenerative or inflammatory/demyelinating CNS conditions such as, Parkinson's disease and frontotemporal dementia
- History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study; major depressive disorder (according to DSM-IV) in the past year; current active depression requiring initiation of treatment (or is believed to account for substantial degree of cognitive impairment)
- Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis serology (unless neurosyphilis was ruled out) or active thyroid dysfunction (particularly suggestive of hypothyroidism), including abnormally high or low serum levels of thyroid stimulating hormone (TSH), where this is thought to be the cause of, or to contribute to the severity of the subject's dementia.
- History of alcohol or other substance abuse, according to the DSM-IV criteria, or recent or remote history of the same if that could be a contributing factor to dementia.
- History of intra cerebral haemorrhage due to any of the following causes: cerebral amyloid angiopathy, uncontrolled hypertension, cerebral arteriovenous malformation, coagulopathy, CNS vasculitis or any other condition that the investigator and/or medical monitor considers as a relevant risk factor for intracerebral haemorrhage
Recent (i.e.,<6 months from Screening Visit) cardiovascular event defined as:
- ST-elevation MI or non-ST-elevation MI, confirmed by cardiac enzyme elevation and ECG changes
- coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft )
- stroke of any etiology
- resuscitated sudden death
- prior carotid surgery or stenting procedure
- Poorly controlled hypertension despite lifestyle modifications and pharmacotherapy (either systolic blood pressure >160mmHg or diastolic blood pressure >110mmHg)
- QTcB interval >450 msec; or QTcB > 480 msec in subjects with bundle branch block based on ECG assessment at the Screening visit.
- HbA1c >12.0 at Screening, or uncontrolled diabetes in the opinion of the investigator.
- History of glaucoma or any other findings in the baseline eye exam that, in the opinion of the investigator, would exclude the subject from participation in the study.
- History of adult asthma (or reactive airway disease) manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s).
- Previous history of anaphylaxis, severe allergic reaction or history of hypersensitivity to any of the components of the formulation.
- Significant abnormalities on clinical chemistry, haematology or urinalysis at Screening, including clinically significant anaemia.
- History of chronic viral hepatitis (including presence of B surface antigen or hepatitis C antibody), or other chronic hepatic disorders.
Abnormal Screening blood tests exceeding any of the limits defined below:
- Alanine transaminase (ALT) or aspartate transaminase (AST) >1.5 x the upper limit of normal (ULN)
- Alkaline phosphatase (AP) and bilirubin >1.5X ULN (isolated bilirubin >1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
- Calculated creatinine clearance < 30 ml/min (per Cockcroft & Gault) at Screening
- Other clinically significant abnormality on physical (including neurological), laboratory or ECG examination that could be detrimental to the subject in the opinion of the Investigator or could compromise the integrity of the study.
- Planned major surgery within the study period.
- Use of systemic steroids or other immunosuppressants within the last 30 days prior to screening.
- Current treatment with barbiturates, MAO inhibitors, butyrophenones, phenothiazines and other "conventional" antipsychotic within 30 days or 5 half-lives prior to Screening, whichever is longer.
- Treatment with antidepressants, (other than MAO inhibitors), thyroid hormones, atypical antipsychotics (e.g. risperidone), benzodiazepines and other sedatives / hypnotics unless prescribed at a stable dose for at least 2 months prior to Screening. Note: Benzodiazepines or other sedatives/hypnotics (including antihistamines) with half-life less than 6 hours can be taken on a prn (as needed) basis but must not be taken within 5 half lives prior to cognitive testing.
- Current treatment with known potent inhibitors of CYP3A4 (e.g. ketoconazole, rifampin, modafinil).
- Current treatment with known potent Pgp inhibitors (itraconazole, ketoconazole, cyclosporin, loperamide, diltiazem, verapamil, spironolactone, quinidine, bepridil, quinine, carvedilol)
- Cognitive tasks prescribed for cognitive rehabilitation and performed under medical supervision in the 6 months prior to screening and/or during study
- Investigational medications or devices including symptomatic AD treatment during the 60 days prior to the Screening visit, or within 5 half-lives of use of the investigational drug prior to the Screening Visit, whichever is longer.
Participation in another investigational drug (with the exception of anti-amyloid monoclonal antibodies [mAbs]) or device study where subject was treated chronically (i.e. > 1 single dose) with a study agent intended to impact AD progression during the 12 months prior to the Screening visit.
- Subjects who participated in an investigational drug study that involved chronic dosing with a monoclonal antibody at any time in the past are excluded from this study, unless it is known that they received placebo during the previous study.
- Subjects who participated in previous single-dose studies of anti-amyloid mAbs will be permitted provided the subject's dose of the mAb is at least 5 half-lives removed; the subjects did not experience any moderate adverse events classified as possibly drug-related or any serious adverse event during that study; the subject did not drop out of the previous study (i.e. completed all safety assessments)
- Subjects, who in the investigator's judgement, pose a significant suicide risk (e.g. history of suicidal behaviour in the last 6 months and/or any suicidal ideation of type 4 or 5 on the C-SSRS in the last 2 months).
- Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff.
Any contraindication to lumbar puncture or insertion of CSF catheter, including but not limited to
- Thrombocytopenia or other coagulation disorders (including subjects receiving coumarin-derived anti-coagulants or low-molecular-weight heparin).
- The presence of cutaneous or soft tissue infection overlying or adjacent to the site of lumbar puncture.
- Previous spinal surgery that could complicate access to the subarachnoid space.
- Suspicion of increased intracranial pressure due to a cerebral mass.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 250mg rilapladib
Experimental drug
|
Experimental Drug
|
Placebo Comparator: placebo
Placebo comparator
|
Placebo comparator
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24
Time Frame: Baseline (Day 0) and Week 24
|
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168).
Change from Baseline in CSF Abeta42 and Abeta40 are summarized.
Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF.
Baseline value was defined as the latest Day 0 value.
Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
The data is presented in for adjusted mean and standard error of adjusted mean.
|
Baseline (Day 0) and Week 24
|
Change From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24
Time Frame: Baseline (Day 0) and Week 24
|
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168).
Change from Baseline in CSF Abeta42/Abeta40 ratio is summarized.
Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF.
Baseline value was defined as the latest Day 0 value.
Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
The data is presented in for adjusted mean and standard error of adjusted mean.
|
Baseline (Day 0) and Week 24
|
Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24
Time Frame: Baseline (Day 0) and Week 24
|
CSF tau and P-tau were assessed at Baseline visit (Day 0) and Week 24 (Day 168).
Change from Baseline in CSF tau and P-tau was summarized.
Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF.
Baseline value was defined as the latest Day 0 value.
Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
The data is presented in for adjusted mean and standard error of adjusted mean.
|
Baseline (Day 0) and Week 24
|
Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24
Time Frame: Baseline (Day 0) and Week 24
|
The WM/EF composite score was comprised of 5 functional tests including 1) Controlled oral word association which measured language fluency, planning and working memory, 2) Category naming: It measures semantic fluency, planning and working memory, 3) One-back: This is a measure of working memory.
4) Trail B: This is a measure of motor speed, visual scanning, and visual-motor integration.
This test required attention and cognitive flexibility.
5) Go No-Go task: This test evaluate accuracy and reaction time for each response.
The composite score calculated by standardizing the total score: sum of all responses obtained from these 5 functional test by using the formula (Total score of ITT population at baseline - Total score at Week 24) /standard deviation of mean total mean score at baseline.
The observed composite score ranged from minimum -1.474 and maximum 1.596.
Lower score means better cognitive status.
Change from Baseline was calculated as post-dose visit minus Baseline value.
|
Baseline (Day 0) and Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline (Day 0) in CSF Albumin Quotients at Week 24
Time Frame: Baseline (Day 0) and Week 24
|
CSF albumin quotient was assessed at Baseline visit (Day 0) and Week 24 (Day 168).
Change from Baseline in albumin quotient is summarized.
Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF.
Baseline value was defined as the latest Day 0 value.
Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
The data is presented in for adjusted mean and standard error of adjusted mean.
|
Baseline (Day 0) and Week 24
|
Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24
Time Frame: Baseline (Day 0) and Week 24
|
Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168).
Change from Baseline in plasma Abeta42 and Abeta40 are summarized.
Baseline value was defined as the latest Day 0 value.
Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
The data is presented in for adjusted mean and standard error of adjusted mean.
|
Baseline (Day 0) and Week 24
|
Change From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24
Time Frame: Baseline (Day 0) and Week 24
|
Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168).
Change from Baseline in plasma Abeta42/Abeta40 ratio is summarized.
Baseline value was defined as the latest Day 0 value.
Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
The data is presented in for adjusted mean and standard error of adjusted mean.
|
Baseline (Day 0) and Week 24
|
Percentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24
Time Frame: Baseline (Day 0) and Week 24
|
Plasma Lp-PLA2 was assessed at Baseline visit (Day 0) and Week 24 (Day 168).
Percentage inhibition in plasma Lp-PLA2 activity ratio is summarized.
Percentage inhibition was calculated by dividing change from Baseline in plasma LpPLA2 by Baseline LpPLA2 multiplied by -100.
Baseline value was defined as the latest Day 0 value.
Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
|
Baseline (Day 0) and Week 24
|
Change From Baseline (Day 0) in CogState Battery Overall Composite Score
Time Frame: Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
|
CogState battery overall composite score comprised of 8 functional tests 1) Controlled oral word association test measured language fluency, planning and working memory.
2) Category naming test measured semantic fluency, planning and working memory.
3) One-back test measured working memory.
4) Trail B test measured motor speed, visual scanning and visual-motor integration, required attention and cognitive flexibility.
5) Go No-Go task evaluated accuracy and reaction time for each response.
6) International shopping list immediate and delayed recall tests measured episodic memory.
7) Identification task test assessed visual attention.
8) Trail A test measured psychomotor speed and attention.
Composite score= total score (sum of all responses from 8 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline.
Score ranged: -1.070 to 0.907.
Lower score indicated the better cognitive status.
Change from Baseline= post-dose visit minus Baseline value
|
Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
|
Change From Baseline (Day 0) in CogState Battery Attention Composite Score
Time Frame: Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
|
CogState battery attention composite score comprised of 2 functional tests including 1) Identification task test assessed visual attention and 2) Trail A test measured psychomotor speed and attention.
Composite score calculated by standardizing the total score (sum of all responses from 2 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline.
The observed composite score ranged from minimum -1.756 and maximum 1.330.
Higher score indicated the better attention.
Baseline value was defined as the latest Day 0 value and Change from Baseline was calculated as post-dose visit minus Baseline value
|
Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 114458
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Study Data/Documents
-
Dataset Specification
Information identifier: 114458Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Individual Participant Data Set
Information identifier: 114458Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Informed Consent Form
Information identifier: 114458Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistical Analysis Plan
Information identifier: 114458Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Study Protocol
Information identifier: 114458Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotated Case Report Form
Information identifier: 114458Information comments: For additional information about this study please refer to the GSK Clinical Study Register
-
Clinical Study Report
Information identifier: 114458Information comments: For additional information about this study please refer to the GSK Clinical Study Register
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer's Disease
-
University of Southern CaliforniaAlzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...RecruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
University of Southern CaliforniaNational Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaboratorsActive, not recruitingDementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited States
-
Novoic LimitedCompletedAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's DiseaseUnited Kingdom
-
Novoic LimitedRecruitingAlzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal CognitionUnited States
-
University Hospital, BordeauxMinistry for Health and Solidarity, FranceCompletedAlzheimer's Disease (AD) | Alzheimer's Disease (AD) Related DisordersFrance
-
University of Colorado, DenverNational Institute on Aging (NIA)Active, not recruitingSuspected Typical Alzheimer's Disease (AD) | Suspected Atypical Alzheimer's Disease (AD)United States
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States